Document Type

Article

Publication Date

5-24-2011

Abstract

This paper reports the findings from a 52-week, open-label trial that assessed the long-term safety and tolerability of aripiprazole adjunctive to antidepressant therapy. Assessment of tolerability was the primary objective of this study, and was evaluated by spontaneous reporting of adverse events, assessment of extrapyramidal symptoms using objective rating scales, and assessment of changes in body weight, fasting plasma lipids, and glucose levels. Specific efficacy findings from this long-term, open-label safety extension phase are also presented. Eligible patients included those who had been previously treated with adjunctive aripiprazole or placebo in two of the previous short-term trials,5,6 as well as de novo subjects with a documented inadequate response to standard antidepressant therapy.

Comments

© 2011 Berman et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

Sabrina Vogel Marler started teaching at Goodwin College as an adjunct in 2014 and became a full-time faculty member in January 2015. At time of publication, she was working for Global Biometric Sciences, Bristol-Myers Squibb in Wallingford, CT.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.